Erythropoietin Falls Short of Neuroprotection in Optic Neuritis

A higher rate of conversion to multiple sclerosis in the placebo group offered a glimmer of hope for treatment in TONE, a phase 3 randomized trial, but caveats loom large. Medscape Medical News
Read More

Leave a Reply

%d bloggers like this: